利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.011 秒)

    Polymorph forms of (2S) - (4E) -N-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
    4.
    发明公开
    Polymorph forms of (2S) - (4E) -N-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders 有权
    （4E）-N-甲基-5 - - [（3-（5-异丙氧基吡啶）基] -4-戊烯-2-胺对羟基苯甲酸酯用于中枢神经系统疾病的治疗中的（2S）多晶型形式

    公开(公告)号：EP2418201A1

    公开(公告)日：2012-02-15

    申请号：EP11167528.6

    申请日：2007-05-08

    申请人： Targacept, Inc.

    发明人： Munoz, Julio A. ,  Dull, Gary Maurice

    IPC分类号： C07D213/63 ,  A61K31/44 ,  A61P25/28

    CPC分类号： C07D213/65

    摘要： Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

    摘要翻译： （2S）的多晶型物形式的 - （4E）-N-甲基-5- [3-（5-异丙氧基吡啶）基] -4-戊烯-2-胺对羟基苯甲酸盐，和它们的制备方法，药物组合物，包含所述多晶型 （一个或多个）和使用，是游离缺失盘。 多晶型物可给药于患者易患或从病症和障碍，：例如中枢神经系统疾病的患者，以治疗和/或预防检查病症。

    Pahrmaceutical compositions for prevention and treatment of central nervous system disorders
    5.
    发明公开
    Pahrmaceutical compositions for prevention and treatment of central nervous system disorders 失效
    对于中枢神经系统的疾病的预防和治疗药物组合物

    公开(公告)号：EP1997806A1

    公开(公告)日：2008-12-03

    申请号：EP08014695.4

    申请日：1997-04-16

    申请人： Targacept, Inc.

    发明人： Caldwell, William Scott ,  Dull, Gary Maurice ,  Dobson, Grayland Page

    IPC分类号： C07D213/38 ,  A61K31/44 ,  A61P25/00

    CPC分类号： C07D213/38

    摘要： Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.

    摘要翻译： 易患或患有中枢神经系统疾病的患者通过施用芳substituiertem脂肪族胺化合物的有效量治疗，芳基烯属substituiertem胺化合物或芳基炔substituiertem胺化合物。 代表性的化合物是（E）-N-甲基-5-（3-吡啶基）-4-戊烯-2-胺。

    Arylvinylazacycloalkane compounds and methods of preparation and use thereof
    6.
    发明公开
    Arylvinylazacycloalkane compounds and methods of preparation and use thereof 有权
    Arylvinylazacycloalkan化合物及其制造方法和用途

    公开(公告)号：EP1947100A1

    公开(公告)日：2008-07-23

    申请号：EP08075106.8

    申请日：2004-03-04

    申请人： Targacept, Inc.

    发明人： Schmitt, Jeffrey Daniel ,  Dull, Gary Maurice ,  Genevois-Borella, Arielle ,  Capet, Marc ,  Cheve, Michel

    IPC分类号： C07D405/14 ,  A61K31/4439 ,  A61P29/00

    CPC分类号： A61K31/506 ,  C07D405/14

    摘要： Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction on nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioural disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

    摘要翻译： 式（I）的新颖vinylazacycloalkane化合物是游离缺失盘。 的化合物是各种nAChRs的的配位体。 的化合物和它们的药学上可接受的盐可用于制备意在预防或治疗与功能障碍上nAChRs的相关病症的药物组合物和/或药物，爱尤其是中枢神经系统或胃肠道系统内。类型障碍的实例也可以治疗 包括神经变性疾病，包括中枢神经系统疾病：例如阿尔茨海默氏病，认知障碍，运动障碍：例如帕金森氏症，药物成瘾，行为障碍和炎性病症，胃肠系统内因此这些化合物可以用作止痛剂在急性治疗， 慢性或复发性疼痛。